Pacer Advisors
TBPH icon

Pacer Advisors’s Theravance Biopharma TBPH Stock Holding History

Pacer Advisors’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-293,192
Closed -$4.76M – 2618
2026
Q1 		$4.76M Sell
293,192
-45,766
-14% -$810K 0.01% 634
2025
Q4 		$6.34M Buy
+338,958
New +$5.62M 0.02% 612

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
ICM
Irenic Capital Management New York $2.08B AUM 19.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Pacer Advisors's TBPH Position: Q2 2026 in Review

Pacer Advisors sold out of Theravance Biopharma (TBPH) in Q2 2026, closing a stake of 293,192 shares — an estimated $4.76M sold.

Pacer Advisors first reported a position in TBPH in Q4 2025 and held it in 2 quarters. The position peaked at $6.34M in Q4 2025. 181 funds tracked by Wall St. Rank hold TBPH as of Q2 2026.

  • Pacer Advisors reported no remaining Theravance Biopharma position as of Q2 2026 after selling out during the quarter.
  • Pacer Advisors sold 293,192 Theravance Biopharma shares in Q2 2026, an estimated $4.76M.
  • Pacer Advisors first reported a position in Theravance Biopharma in Q4 2025 and held it in 2 quarters.
  • Pacer Advisors's Theravance Biopharma position peaked at $6.34M in Q4 2025.
  • 181 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2026.

Based on Pacer Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.